The present invention relates to identifying the risk of a subject
developing renal stones utilizing an assessment of PTH agonist,
antagonist and/or total PTH levels, optionally together with an
assessment of serum and/or urine calcium levels and/or other analytes.
The present description further relates to monitoring and guiding
treatment for renal stones and kits useful therefore.